A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Overview of attention for article published in Alzheimer's Research & Therapy, April 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#3 of 1,500)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 126 news outlets
blogs: 5 blogs
twitter: 73 X users

patent: 1 patent
facebook: 1 Facebook page
wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 421 Dimensions

Readers on

mendeley: 529 Mendeley

Summary News Blogs X Patents Facebook Wikipedia Dimensions citations

So far, Altmetric has seen 5 posts from 5 blogs.

Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials

Cell, 16 Oct 2023

Alzheimer’s disease (AD) research has entered a new era with the recent positive phase 3 clinical trials of the anti-Aβ…

Alzheimer’s Treatment Targets

Psychology Today, 28 Jun 2023

Amyloid, inflammation, or both?

Alzheimer’s disease: Is amyloid beta 42 the answer?

Mapping Ignorance, 17 Oct 2022

Authors: Andrea Sturchio, MD, PhD Student, Clinical Neuroscience, Karolinska Institutet; Kariem Ezzat, Research Scientist…

Researchers Have a New Theory About What Causes Alzheimer's, And It's Not Plaque

Science Alert, 15 Oct 2022

This could be big.

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity, including 1 additional blog posts.